Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.35 |
| ▸ | UBE2N | P61088 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11929579 | 0.83 | TDP1 (0.40) | MAPK1KDM4EL3MBTL1MLYCDDYRK1A | |
| SCHEMBL1976172 | 0.82 | PIK3CD (0.43) | MAPK1DEGS1KDM4EGRIN2BDYRK1A | |
| SCHEMBL5266868 | 0.81 | DYRK1A (0.46) | MAPK1TRPM8KDM4EL3MBTL1DYRK1A | |
| SCHEMBL2880365 | 0.81 | PDK2 (0.39) | MAPK1TRPM8KDM4EL3MBTL1MLYCD | |
| SCHEMBL256758 | 0.81 | ALDH1A1 (0.53) | MAPK1KDM4EL3MBTL1MLYCDMEN1 | |
| SCHEMBL17140935 | 0.81 | PDK2 (0.38) | MAPK1TRPM8KDM4EL3MBTL1MLYCD | |
| SCHEMBL7139611 | 0.81 | P4HTM (0.40) | MAPK1KDM4EL3MBTL1MLYCD | |
| SCHEMBL1223723 | 0.81 | RAB9A (0.45) | MAPK1L3MBTL1MEN1KMT2A | |
| SCHEMBL31003087 | 0.81 | POLB (0.40) | MAPK1KDM4EL3MBTL1MLYCDDYRK1A | |
| SCHEMBL5524906 | 0.79 | L3MBTL1 (0.42) | MAPK1KDM4EL3MBTL1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119684303-A | Heterocyclic compound of difunctional degradable androgen receptor and application thereof | 上海超阳药业有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-117285516-A | Dehydrogenated phenyl achyranthis statin compound, preparation method and application thereof | 大连万众益生大健康有限公司 | 2023-12-26 | — | — | CN | disclosed |
| EP-2601192-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-9309211-B2 | Arylalkene derivatives and use thereof as selective estrogen receptor modulators | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2016-04-12 | — | — | US | disclosed |
| US-9309211-B2 | Arylalkene derivatives and use thereof as selective estrogen receptor modulators | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2016-04-12 | — | — | US | disclosed |
| US-9309211-B2 | Arylalkene derivatives and use thereof as selective estrogen receptor modulators | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2016-04-12 | — | — | US | disclosed |
| US-9029536-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-12 | — | — | US | disclosed |
| EP-2797889-A1 | NOVEL ARYLALKENE DERIVATIVES AND USE THEREOF AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | Centaurus Biopharma Co., Ltd. (CN) | 2014-11-05 | — | — | EP | disclosed |
| US-20130172292-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
| WO-2013097773-A1 | NOVEL ARYLALKENE DERIVATIVES AND USE THEREOF AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013097773-A1 | NOVEL ARYLALKENE DERIVATIVES AND USE THEREOF AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2013-07-04 | — | — | WO | disclosed |
| EP-2601192-A1 | FUSED HETEROCYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2013-06-12 | — | — | EP | disclosed |
| WO-2012018909-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172292-A1 | FUSED HETEROCYCLIC COMPOUNDS | PDE10A, PDE3A, PDE2A | MAPK1 1583/4885DEGS1 3135/4885TRPM8 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.